You are here

Our science / Clinical Trials / Find a Trial / NCT00366327

Study Evaluating Bifeprunox in Patients With Schizophrenia.

Back to Search Print Save as PDF Bookmark Trial

NCT00366327

Last updated on December 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Little Rock, Arkansas, 72201 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-66 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Outpatients who have successfully completed Wyeth study 3168A1-313.

2. A signed and dated informed consent form for this study.

3. No major protocol violations in the previous study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Clinically important abnormalities in the preceding short-term study that have not
resolved.

2. Use of prohibited treatments in the preceding short-term study.

3. Meeting any exclusion criteria in the preceding short-term study

NCT00366327
Pfizer
Terminated
Study Evaluating Bifeprunox in Patients With Schizophrenia.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]com

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Schizophrenia
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
NCT00567203
All Genders
18+
Years
Multiple Sites
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
NCT00458107
Females
20+
Years
Glendale, California
Schizophrenia
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063
All Genders
18+
Years
Multiple Sites
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
NCT00650611
All Genders
10+
Years
Multiple Sites
Study Evaluating Bifeprunox in Patients With Schizophrenia.
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Schizophrenia
Drug: Bifeprunox
Flex dose (20 or 30 mg)tablet, QD for 1 year
Experimental: A
Intervention: Drug: Bifeprunox
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
400
March 2008
March 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Outpatients who have successfully completed Wyeth study 3168A1-313.
  2. A signed and dated informed consent form for this study.
  3. No major protocol violations in the previous study.

Exclusion Criteria:

  1. Clinically important abnormalities in the preceding short-term study that have not resolved.
  2. Use of prohibited treatments in the preceding short-term study.
  3. Meeting any exclusion criteria in the preceding short-term study
Sexes Eligible for Study: All
18 Years to 66 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00366327
3168A1-314
B3101010 ( Other Identifier: Pfizer )
No
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
April 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now